Anzeige
Mehr »
Donnerstag, 09.10.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JXW7 | ISIN: US88322Q1085 | Ticker-Symbol: NKB2
Tradegate
09.10.25 | 09:32
30,395 Euro
-1,15 % -0,355
Branche
Pharma
Aktienmarkt
S&P SmallCap 600
1-Jahres-Chart
TG THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
TG THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
30,40531,17009:51
30,40531,17009:51

Aktuelle News zur TG THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoH.C. Wainwright initiates TG Therapeutics stock with Buy rating on MS drug growth1
MoH.C. Wainwright stuft TG Therapeutics mit "Buy" ein - MS-Medikament Briumvi als Wachstumstreiber10
24.09.TG Therapeutics' MS drug shows low relapse rate after six years4
24.09.TG Therapeutics, Inc.: New Data for BRIUMVI Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment253During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment Overall safety profile of BRIUMVI...
► Artikel lesen
10.09.TG Therapeutics, Inc.: TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting2
08.09.TG Therapeutics hebt Prognose an: Strategische Offensive im Markt für Multiple Sklerose6
08.09.TG Therapeutics begins phase 3 trial of subcutaneous MS treatment9
TG THERAPEUTICS Aktie jetzt für 0€ handeln
08.09.TG Therapeutics startet Phase-3-Studie für subkutane MS-Behandlung2
08.09.TG Therapeutics, Inc.: TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment148NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy)...
► Artikel lesen
03.09.TG Therapeutics announces $100M share buyback program2
03.09.TG Therapeutics CEO Voices Strong Conviction In Briumvi With New $100 Million Buyback1
03.09.TG Therapeutics completes $100 million share buyback, approves new program6
03.09.TG Therapeutics, Inc.: TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program3
11.08.TG THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans6
08.08.TG Therapeutics files automatic mixed securities shelf7
08.08.TG THERAPEUTICS, INC. - 10-Q, Quarterly Report1
05.08.TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line5
04.08.Briumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide8
04.08.Why Top 3% Stock TG Therapeutics Crashed Despite Raising Its 2025 Outlook14
04.08.TG Therapeutics falls after Q2 miss despite guidance raise17
Weiter >>
49 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3